Esperion Therapeutics Inc (ESPR) 60.28 $ESPR
Hypercholesterolemia Therapeutics Pipeline Review, H1 2015 - Analysis of 31 Companies & 59 Drug Profiles
M2 - Fri Jul 31, 8:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/svlgpj/hypercholesterolem) has announced the addition of the "Hypercholesterolemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hypercholesterolemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypercholesterolemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aegerion Pharmaceuticals, Inc. - Alnylam Pharmaceuticals, Inc. - Amgen Inc. - AtheroNova Inc. - Bristol-Myers Squibb Company - Catabasis Pharmaceuticals, Inc. - Cerenis Therapeutics Holding SA - CrystalGenomics, Inc. - CymaBay Therapeutics, Inc. - Daewon Pharm Co. Ltd. - Dybly AG - Eli Lilly and Company - Esperion Therapeutics, Inc. - F. Hoffmann-La Roche Ltd. - Hanmi Pharmaceuticals, Co. Ltd. - Immune Response BioPharma, Inc. - Johnson & Johnson - Kadmon Corporation, LLC - Kowa Company, Ltd. - Merck & Co., Inc. - Michigan Life Therapeutics, LLC - Novartis AG - Pfizer Inc. - Planet Biotechnology Inc. - Regeneron Pharmaceuticals, Inc. - Sanofi - Serometrix, LLC - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Thetis Pharmaceuticals LLC - uniQure N.V. - Zhejiang Hisun Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/sv...lesterolem
PFE: 35.82 (-0.29), AMGN: 176.44 (+1.64), AEGR: 19.25 (-0.27), LLY: 84.73 (+0.68), BMY: 65.06 (+0.22), JNJ: 100.52 (+0.72), ESPR: 60.28 (-1.64), MRK: 59.10 (+0.40), CBAY: 2.95 (-0.04), REGN: 592.40 (+11.46), NVS: 103.25 (-0.32)
Troubled Stocks Go From Worst to First
at The Street - Wed Jul 29, 3:05PM CDT
Oil- and commodity-related shares perform well.
BIIB: 335.41 (+5.03), ESPR: 60.28 (-1.64), VDSI: 19.61 (+0.81), FB: 96.44 (+2.38), BEAT: 11.87 (-0.23), DATA: 103.94 (+2.76)
Sorry, No Fed Effect Today
at The Street - Wed Jul 29, 1:22PM CDT
The market did its usual jig on the news and went along its merry way.
BIIB: 335.41 (+5.03), ESPR: 60.28 (-1.64), VDSI: 19.61 (+0.81), FB: 96.44 (+2.38), BEAT: 11.87 (-0.23), DATA: 103.94 (+2.76)
Make Sure You Don't Get Caught in a Breakdown
at The Street - Wed Jul 29, 9:11AM CDT
Nothing much sticks out to the upside right now.
BIIB: 335.41 (+5.03), ESPR: 60.28 (-1.64), VDSI: 19.61 (+0.81), FB: 96.44 (+2.38), BEAT: 11.87 (-0.23), DATA: 103.94 (+2.76)
Esperion Therapeutics to Provide Second Quarter Program Updates and Financial Results
Marketwired - Wed Jul 29, 7:31AM CDT
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced it will host a conference call and webcast to provide program updates and financial results for the second quarter 2015. The conference call and webcast will take place on Thursday, August 6, 2015 at 4:30 p.m. Eastern Time.
ESPR: 60.28 (-1.64)
Esperion Therapeutics Announces Positive Top-Line Phase 2 Results for ETC-1002 in Patients With Hypercholesterolemia and Hypertension
Marketwired - Tue Jul 28, 6:30AM CDT
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers, today announced positive top-line results from ETC-1002-014, a Phase 2 exploratory study evaluating the safety and efficacy of ETC-1002 (bempedoic acid) in patients with both hypercholesterolemia and hypertension.
ESPR: 60.28 (-1.64)
Regeneron/Sanofi PCSK9 Cholesterol Drug Wins FDA OK
at Investor's Business Daily - Fri Jul 24, 4:24PM CDT
Praluent, the new cholesterol-busting drug from Regeneron Pharmaceuticals (REGN) and Sanofi (SNY), was granted FDA approval Friday, but for a slightly more limited patient pool than some had hoped. Regeneron stock closed down 2.7% to 541.85 on the...
ESPR: 60.28 (-1.64), MDCO: 31.77 (+0.75), PFE: 35.82 (-0.29), AMGN: 176.44 (+1.64), SNY: 54.71 (+1.22), REGN: 592.40 (+11.46)
Esperion Therapeutics to Host Second Annual Analyst and Investor Day
Marketwired - Thu Jul 23, 3:30PM CDT
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced that it will host its second annual analyst and investor day event and webcast for institutional investors and research analysts on Thursday, July 30 at 8:30 a.m. Eastern Time.
ESPR: 60.28 (-1.64)
Acute Coronary Syndrome Therapeutics Pipeline Report 2015 - 15 Companies & 23 Drug Profiles
M2 - Tue Jul 21, 5:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qf9st8/acute_coronary) has announced the addition of the "Acute Coronary Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Coronary Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - advanceCor GmbH - Arena Pharmaceuticals, Inc. - Artery Therapeutics, Inc. - AstraZeneca PLC - Athera Biotechnologies AB - Auspex Pharmaceuticals, Inc. - Bayer AG - Esperion Therapeutics, Inc. - GlaxoSmithKline Plc - Lee's Pharmaceutical Holdings Limited - MedImmune, LLC - Pfizer Inc. - The Medicines Company - Vitae Pharmaceuticals, Inc. - XOMA Corporation Drug Profiles - 4-WF - AEM-28 - AEM-28-02 - Artpep-2 - Biologics for Acute Coronary Syndrome - bivalirudin - cangrelor - COR-2 - COR-3 - gevokizumab - losmapimod - MDCO-216 - MEDI-6012 - MTP-131 - PC-mAb - PF-06282999 - PMC-6 - PR-15 - rivaroxaban - SD-970 - temanogrel hydrochloride - VTP-38443 - ZK-001 For more information visit http://www.researchandmarkets.com/research/qf...e_coronary
ESPR: 60.28 (-1.64), PFE: 35.82 (-0.29), AZN: 34.54 (+0.20), VTAE: 9.55 (-0.06), ASPX: 100.96 (unch), GSK: 44.17 (+0.72), ARNA: 4.03 (-0.02), XOMA: 0.90 (+0.12)
Critical Alerts For FireEye, Ariad Pharmaceuticals, ACADIA Pharmaceuticals, Esperion Therapeutics and Humana Released By InvestorsObserver
PR Newswire - Wed Jul 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FEYE, ARIA, ACAD, ESPR and HUM.
ESPR: 60.28 (-1.64), ACAD: 47.60 (-0.10), FEYE: 44.56 (+1.11), ARIA: 7.74 (-0.35), HUM: 185.54 (+3.21)
The FDA Breathes New Life Into Esperion's ETC-1002
Todd Campbell, The Motley Fool - Motley Fool - Thu Jul 09, 7:53AM CDT
Worries that the FDA would raise the bar for cholesterol-fighting drugs seeking future approval sent high-flying Esperion Therapeutics lower over the past month, but a new decision by the FDA to lift a clinical hold on the use of high doses of the...
ESPR: 60.28 (-1.64)
Esperion Therapeutics (ESPR) Jumps: Stock Rises 7.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 08, 8:25AM CDT
Esperion Therapeutics (ESPR) was a big mover last session, with shares rising over 7% on the day.
ESPR: 60.28 (-1.64), PTLA: 50.27 (-1.03)
Esperion Therapeutics Announces Removal of 240 mg Partial Clinical Hold for ETC-1002
Marketwired - Tue Jul 07, 7:02AM CDT
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced the U.S. Food and Drug Administration (FDA) has removed the 240 mg partial clinical hold on ETC-1002 (bempedoic acid). This action by FDA will now allow ETC-1002 to be used at doses above 240 mg in clinical studies. Esperion plans to initiate the Phase 3 clinical program for ETC-1002 in the fourth quarter of this year using the already optimized 180 mg dose.
ESPR: 60.28 (-1.64)
Critical Alerts For FireEye, Petrobras, Impac Mortgage Holdings Inc, Esperion Therapeutics and Palo Alto Networks Released By InvestorsObserver
PR Newswire - Thu Jul 02, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FEYE, PBR, IMH, ESPR and PANW.
PBR: 6.32 (-0.13), ESPR: 60.28 (-1.64), FEYE: 44.56 (+1.11), IMH: 20.58 (+0.31), PANW: 190.27 (+4.77)
Healthcare ratings roundup - new coverage
Seeking Alpha - at Seeking Alpha - Tue Jun 30, 10:11AM CDT
ISRG: 531.07 (+4.32), ESPR: 60.28 (-1.64), PTLA: 50.27 (-1.03), HRTX: 33.63 (+0.70), GEN: 6.58 (+0.56), SCLN: 9.15 (+0.04), GI: 16.45 (unch)
Hypercholesterolemia Therapeutics Pipeline Review, H1 2015 - Analysis of 31 Companies & 59 Drug Profiles
M2 - Fri Jul 31, 8:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/svlgpj/hypercholesterolem) has announced the addition of the "Hypercholesterolemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hypercholesterolemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypercholesterolemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aegerion Pharmaceuticals, Inc. - Alnylam Pharmaceuticals, Inc. - Amgen Inc. - AtheroNova Inc. - Bristol-Myers Squibb Company - Catabasis Pharmaceuticals, Inc. - Cerenis Therapeutics Holding SA - CrystalGenomics, Inc. - CymaBay Therapeutics, Inc. - Daewon Pharm Co. Ltd. - Dybly AG - Eli Lilly and Company - Esperion Therapeutics, Inc. - F. Hoffmann-La Roche Ltd. - Hanmi Pharmaceuticals, Co. Ltd. - Immune Response BioPharma, Inc. - Johnson & Johnson - Kadmon Corporation, LLC - Kowa Company, Ltd. - Merck & Co., Inc. - Michigan Life Therapeutics, LLC - Novartis AG - Pfizer Inc. - Planet Biotechnology Inc. - Regeneron Pharmaceuticals, Inc. - Sanofi - Serometrix, LLC - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Thetis Pharmaceuticals LLC - uniQure N.V. - Zhejiang Hisun Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/sv...lesterolem
PFE: 35.82 (-0.29), AMGN: 176.44 (+1.64), AEGR: 19.25 (-0.27), LLY: 84.73 (+0.68), BMY: 65.06 (+0.22), JNJ: 100.52 (+0.72), ESPR: 60.28 (-1.64), MRK: 59.10 (+0.40), CBAY: 2.95 (-0.04), REGN: 592.40 (+11.46), NVS: 103.25 (-0.32)
Troubled Stocks Go From Worst to First
at The Street - Wed Jul 29, 3:05PM CDT
Oil- and commodity-related shares perform well.
BIIB: 335.41 (+5.03), ESPR: 60.28 (-1.64), VDSI: 19.61 (+0.81), FB: 96.44 (+2.38), BEAT: 11.87 (-0.23), DATA: 103.94 (+2.76)
Sorry, No Fed Effect Today
at The Street - Wed Jul 29, 1:22PM CDT
The market did its usual jig on the news and went along its merry way.
BIIB: 335.41 (+5.03), ESPR: 60.28 (-1.64), VDSI: 19.61 (+0.81), FB: 96.44 (+2.38), BEAT: 11.87 (-0.23), DATA: 103.94 (+2.76)
Make Sure You Don't Get Caught in a Breakdown
at The Street - Wed Jul 29, 9:11AM CDT
Nothing much sticks out to the upside right now.
BIIB: 335.41 (+5.03), ESPR: 60.28 (-1.64), VDSI: 19.61 (+0.81), FB: 96.44 (+2.38), BEAT: 11.87 (-0.23), DATA: 103.94 (+2.76)
Esperion Therapeutics to Provide Second Quarter Program Updates and Financial Results
Marketwired - Wed Jul 29, 7:31AM CDT
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced it will host a conference call and webcast to provide program updates and financial results for the second quarter 2015. The conference call and webcast will take place on Thursday, August 6, 2015 at 4:30 p.m. Eastern Time.
ESPR: 60.28 (-1.64)
Esperion Therapeutics Announces Positive Top-Line Phase 2 Results for ETC-1002 in Patients With Hypercholesterolemia and Hypertension
Marketwired - Tue Jul 28, 6:30AM CDT
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers, today announced positive top-line results from ETC-1002-014, a Phase 2 exploratory study evaluating the safety and efficacy of ETC-1002 (bempedoic acid) in patients with both hypercholesterolemia and hypertension.
ESPR: 60.28 (-1.64)
Regeneron/Sanofi PCSK9 Cholesterol Drug Wins FDA OK
at Investor's Business Daily - Fri Jul 24, 4:24PM CDT
Praluent, the new cholesterol-busting drug from Regeneron Pharmaceuticals (REGN) and Sanofi (SNY), was granted FDA approval Friday, but for a slightly more limited patient pool than some had hoped. Regeneron stock closed down 2.7% to 541.85 on the...
ESPR: 60.28 (-1.64), MDCO: 31.77 (+0.75), PFE: 35.82 (-0.29), AMGN: 176.44 (+1.64), SNY: 54.71 (+1.22), REGN: 592.40 (+11.46)
Esperion Therapeutics to Host Second Annual Analyst and Investor Day
Marketwired - Thu Jul 23, 3:30PM CDT
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced that it will host its second annual analyst and investor day event and webcast for institutional investors and research analysts on Thursday, July 30 at 8:30 a.m. Eastern Time.
ESPR: 60.28 (-1.64)
Acute Coronary Syndrome Therapeutics Pipeline Report 2015 - 15 Companies & 23 Drug Profiles
M2 - Tue Jul 21, 5:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qf9st8/acute_coronary) has announced the addition of the "Acute Coronary Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Coronary Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - advanceCor GmbH - Arena Pharmaceuticals, Inc. - Artery Therapeutics, Inc. - AstraZeneca PLC - Athera Biotechnologies AB - Auspex Pharmaceuticals, Inc. - Bayer AG - Esperion Therapeutics, Inc. - GlaxoSmithKline Plc - Lee's Pharmaceutical Holdings Limited - MedImmune, LLC - Pfizer Inc. - The Medicines Company - Vitae Pharmaceuticals, Inc. - XOMA Corporation Drug Profiles - 4-WF - AEM-28 - AEM-28-02 - Artpep-2 - Biologics for Acute Coronary Syndrome - bivalirudin - cangrelor - COR-2 - COR-3 - gevokizumab - losmapimod - MDCO-216 - MEDI-6012 - MTP-131 - PC-mAb - PF-06282999 - PMC-6 - PR-15 - rivaroxaban - SD-970 - temanogrel hydrochloride - VTP-38443 - ZK-001 For more information visit http://www.researchandmarkets.com/research/qf...e_coronary
ESPR: 60.28 (-1.64), PFE: 35.82 (-0.29), AZN: 34.54 (+0.20), VTAE: 9.55 (-0.06), ASPX: 100.96 (unch), GSK: 44.17 (+0.72), ARNA: 4.03 (-0.02), XOMA: 0.90 (+0.12)
Critical Alerts For FireEye, Ariad Pharmaceuticals, ACADIA Pharmaceuticals, Esperion Therapeutics and Humana Released By InvestorsObserver
PR Newswire - Wed Jul 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FEYE, ARIA, ACAD, ESPR and HUM.
ESPR: 60.28 (-1.64), ACAD: 47.60 (-0.10), FEYE: 44.56 (+1.11), ARIA: 7.74 (-0.35), HUM: 185.54 (+3.21)
The FDA Breathes New Life Into Esperion's ETC-1002
Todd Campbell, The Motley Fool - Motley Fool - Thu Jul 09, 7:53AM CDT
Worries that the FDA would raise the bar for cholesterol-fighting drugs seeking future approval sent high-flying Esperion Therapeutics lower over the past month, but a new decision by the FDA to lift a clinical hold on the use of high doses of the...
ESPR: 60.28 (-1.64)
Esperion Therapeutics (ESPR) Jumps: Stock Rises 7.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 08, 8:25AM CDT
Esperion Therapeutics (ESPR) was a big mover last session, with shares rising over 7% on the day.
ESPR: 60.28 (-1.64), PTLA: 50.27 (-1.03)
Esperion Therapeutics Announces Removal of 240 mg Partial Clinical Hold for ETC-1002
Marketwired - Tue Jul 07, 7:02AM CDT
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced the U.S. Food and Drug Administration (FDA) has removed the 240 mg partial clinical hold on ETC-1002 (bempedoic acid). This action by FDA will now allow ETC-1002 to be used at doses above 240 mg in clinical studies. Esperion plans to initiate the Phase 3 clinical program for ETC-1002 in the fourth quarter of this year using the already optimized 180 mg dose.
ESPR: 60.28 (-1.64)
Critical Alerts For FireEye, Petrobras, Impac Mortgage Holdings Inc, Esperion Therapeutics and Palo Alto Networks Released By InvestorsObserver
PR Newswire - Thu Jul 02, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FEYE, PBR, IMH, ESPR and PANW.
PBR: 6.32 (-0.13), ESPR: 60.28 (-1.64), FEYE: 44.56 (+1.11), IMH: 20.58 (+0.31), PANW: 190.27 (+4.77)
Healthcare ratings roundup - new coverage
Seeking Alpha - at Seeking Alpha - Tue Jun 30, 10:11AM CDT
ISRG: 531.07 (+4.32), ESPR: 60.28 (-1.64), PTLA: 50.27 (-1.03), HRTX: 33.63 (+0.70), GEN: 6.58 (+0.56), SCLN: 9.15 (+0.04), GI: 16.45 (unch)
